{{Rsnum
|rsid=9730073
|Gene=FMN2
|Chromosome=1
|position=240392735
|Orientation=plus
|GMAF=0.3972
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=FMN2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 24.6 | 46.2 | 29.2
| HCB | 40.9 | 43.2 | 15.9
| JPT | 65.9 | 34.1 | 0.0
| YRI | 68.9 | 27.9 | 3.3
| ASW | 0.0 | 0.0 | 0.0
| CHB | 40.9 | 43.2 | 15.9
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs9730073
|Name_s=
|Gene_s=FMN2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.000008. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109400
}}

{{PharmGKB
|RSID=rs9730073
|Name_s=
|Gene_s=FMN2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. In combination, rs278917, rs10061997, rs12190776, rs2784917, and rs9730073 were all significant predictors of etoposide IC50, and accounted for 40% of the etoposide IC50 variation in Yorubans. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.000005. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109399
}}

{{PMID|18451141|OA=1
}} Genetic variants contributing to daunorubicin-induced cytotoxicity.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs9730073
|overall_frequency_n=81
|overall_frequency_d=124
|overall_frequency=0.653226
|n_genomes=47
|n_genomes_annotated=0
|n_haplomes=75
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}